-GENSCIENCES

Background

Established in 2019 and headquartered in BioSpark, GENSCIENCES is a biopharmaceutical company integrating innovative drug R&D, clinical research, production, and commercialization. Leveraging an advanced long-acting biologics platform, the company focuses on addressing unmet needs in hemophilia by developing next-generation therapies with global best-in-class potential.

It operates R&D centers in Beijing and Zhengzhou, and an early commercial production base in Shanghai. The Nantong project includes a biopharmaceutical research institute and an annual production capacity of 32.5 million doses of long-acting recombinant coagulation factors, metabolic disease drugs, and macromolecular anti-tumor drugs.

Case details

• Total Investment: RMB 5 billion

• Site Area: 85,333 m²

• Floor Area: 125,000 m²

• Projected Annual Output: RMB 4.1 billion